» Articles » PMID: 39129243

How to Use Continuous Glucose Monitoring Efficiently in Diabetes Management: Opinions and Recommendations by German Experts on the Status and Open Questions

Abstract

Today, continuous glucose monitoring (CGM) is a standard diagnostic option for patients with diabetes, at least for those with type 1 diabetes and those with type 2 diabetes on insulin therapy, according to international guidelines. The switch from spot capillary blood glucose measurement to CGM was driven by the extensive and immediate support and facilitation of diabetes management CGM offers. In patients not using insulin, the benefits of CGM are not so well studied/obvious. In such patients, factors like well-being and biofeedback are driving CGM uptake and outcome. Apps can combine CGM data with data about physical activity and meal consumption for therapy adjustments. Personalized data management and coaching is also more feasible with CGM data. The same holds true for digitalization and telemedicine intervention ("virtual diabetes clinic"). Combining CGM data with Smart Pens ("patient decision support") helps to avoid missing insulin boluses or insulin miscalculation. Continuous glucose monitoring is a major pillar of all automated insulin delivery systems, which helps substantially to avoid acute complications and achieve more time in the glycemic target range. These options were discussed by a group of German experts to identify concrete gaps in the care structure, with a view to the necessary structural adjustments of the health care system.

Citing Articles

Is Continuous Glucose Monitoring Feasible in Tribal India? Navigating the Benefits and Overcoming the Challenges.

Singh K, Chakma T, Nagwanshi A, Shrivastava S J Diabetes Sci Technol. 2024; 19(2):600-601.

PMID: 39578683 PMC: 11585006. DOI: 10.1177/19322968241302056.

References
1.
Montaser E, Fabris C, Kovatchev B . Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes. Diabetes Technol Ther. 2022; 24(11):797-804. DOI: 10.1089/dia.2022.0104. View

2.
Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K . Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost. 2004; 2(8):1453-9. DOI: 10.1111/j.1538-7836.2004.00835.x. View

3.
Van Beers C, DeVries J, Kleijer S, Smits M, Geelhoed-Duijvestijn P, Kramer M . Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016; 4(11):893-902. DOI: 10.1016/S2213-8587(16)30193-0. View

4.
Petrie J, Peters A, Bergenstal R, Holl R, Fleming G, Heinemann L . Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017; 40(12):1614-1621. DOI: 10.2337/dci17-0043. View

5.
Donahue R, Abbott R, Reed D, Yano K . Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987; 36(6):689-92. DOI: 10.2337/diab.36.6.689. View